Ovarian response to controlled ovarian hyperstimulation in women with cancer is as expected according to an age-specific nomogram
- 198 Downloads
To evaluate the ovarian response to controlled ovarian hyperstimulation (COH) in cancer patients according to an age-specific nomogram for the number of retrieved oocytes.
Retrospective observational study carried out in a University affiliated fertility clinic. Forty-eight patients with cancer underwent ovarian stimulation for oocyte cryopreservation. An age - specific nomogram for the number of retrieved oocytes was built with 1536 IVF cycles due to male factor exclusively, oocyte donation and age related fertility preservation. The number of oocytes retrieved in cancer patients was compared to the expected response according to the nomogram using the Z-score.
The mean number of total retrieved oocytes in patients with cancer was 14.04 ± 8.83. After applying the Z-score to compare the number of retrieved oocytes between women with cancer and the expected response according to the age-specific nomogram, we did not observe a statistically significant difference (Z-score 0.23; 95 % CI [−0.13-0.60]).
According to our results, patients with cancer exhibit an ovarian response as expected by age. Despite the limitation of the sample size, the obtained results should encourage oncologists for early referral of women with cancer to fertility specialists.
KeywordsFertility preservation Cancer Controlled ovarian hyperstimulation Ovarian response Nomogram
This work was performed under the auspices of “Catedra d’Investigació en Obstetricia i Ginecología” of Department of Obstetrics, Gynaecology and Reproductive Medicine; Hospital Universitari Quirón-Dexeus, Universitat Autònoma de Barcelona.
- 7.Mature oocyte cryopreservation: a guideline. Fertil Steril. 2013;99:37–43.Google Scholar
- 15.Rigby RA, Stasinopoulos DM. Generalized additive models for location, scale and shape (with discussion). Appl Stat. 2005;54:507–54.Google Scholar
- 17.Fatum M, McVeight E, Child T. The case for aromatase inhibitors use in Oncofertility patients. Should aromatase inhibitors be combined with gonadotropina treatment in Breast Cancer patients undergoing ovarian stimulation for fertiity preservation prior to chemotherapy? A debate. Hum Fertil. 2013;16:235–40.CrossRefGoogle Scholar
- 22.Lawrenz B, Fehm T, von Wolff M, Soekler M, Huebner S, Henes J, et al. Reduced pretreatment ovarian reserve in premenopausal female patients with Hodgkin lymphoma or non-Hodgkin-lymphoma—evaluation by using antimüllerian hormone and retrieved oocytes. Fertil Steril. 2012;98:141–4.PubMedCrossRefGoogle Scholar
- 30.Fauser BC, de Jong D, Olivennes F, Wramsby H, Tay C, Itskovitz-Eldor J, et al. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after Cotreatment with the GnRH antagonist Ganirelix during ovarian hyperstimulation for in vitro fertilization. J Clin Endocrinol Metab. 2002;87:709–15.PubMedCrossRefGoogle Scholar